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Abstract
Purpose: This work investigates how short-term changes in blood glucose concentration affect the refractive components
of the diabetic eye in patients with long-term Type 1 and Type 2 diabetes.
Methods: Blood glucose concentration, refractive error components (mean spherical equivalent MSE, J0, J45), central
corneal thickness (CCT), anterior chamber depth (ACD), crystalline lens thickness (LT), axial length (AL) and ocular
aberrations were monitored at two-hourly intervals over a 12-hour period in: 20 T1DM patients (mean age 6 SD) 38614
years, baseline HbA1c 8.661.9%; 21 T2DM patients (mean age 6 SD) 56611 years, HbA1c 7.561.8%; and in 20 control
subjects (mean age 6 SD) 49623 years, HbA1c 5.560.5%. The refractive and biometric results were compared with the
corresponding changes in blood glucose concentration.
Results: Blood glucose concentration at different times was found to vary significantly within (p,0.0005) and between
groups (p,0.0005). However, the refractive error components and ocular aberrations were not found to alter significantly
over the day in either the diabetic patients or the control subjects (p.0.05). Minor changes of marginal statistical or optical
significance were observed in some biometric parameters. Similarly there were some marginally significant differences
between the baseline biometric parameters of well-controlled and poorly-controlled diabetic subjects.
Conclusion: This work suggests that normal, short-term fluctuations (of up to about 6 mM/l on a timescale of a few hours)
in the blood glucose levels of diabetics are not usually associated with acute changes in refractive error or ocular wavefront
aberrations. It is therefore possible that factors other than refractive error fluctuations are sometimes responsible for the
transient visual problems often reported by diabetic patients.
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Introduction
The effects of diabetes mellitus (DM) on the anterior structures
of the eye are less frequently reported than its effects on the retina.
However, anterior ocular changes can also lead to visual problems.
The bulk of the relevant literature describes changes in refractive
error due to fluctuating blood glucose levels. These typically occur
soon after the onset of treatment for diabetes [1,2,3,4,5]; they may
be either acute (short-term) or chronic (long-term), and either
myopic [1,2,3,6] or hyperopic [4,5,7].
It has been suggested that diabetes-induced changes occurring
in the aqueous humour [8,9], cornea [10,11,12] and crystalline
lens [13,14,15] could play a key role in refractive fluctuations. It is
hypothesized that glucose enters the crystalline lens via the
aqueous humour by a process of facilitated diffusion. Some
experimental studies suggest that, in diabetes, hyperglycemia leads
to an excessive uptake of glucose into the lens cells and fibres,
which activates alternative routes for glucose handling such as the
aldose reductase pathway. This instigates intracellular accumula-
tion of sorbitol [16] followed by lenticular swelling [17], which
causes a myopic shift. During hyperglycemia, the increased flux of
glucose through the polyol pathway accounts for as much as one-
third of the total glucose turnover [18,19]. Aldose reductase-
induced osmotic stress seems to be the cause of diabetic cataract
[20]. Conversely, a decrease in glucose concentration in the
aqueous humour is predicted to change the osmotic pressure
between the aqueous humour, lens and vitreous humour with a
decrease in the refractive index of the lens, leading to a hyperopic
refractive shift [21]. The exact effects are likely to be complex and
to vary with the individual patient, since the power of the lens will
PLOS ONE | www.plosone.org 1 December 2012 | Volume 7 | Issue 12 | e52947
be affected by any changes in thickness, surface curvature and
gradient of refractive index, and these changes will depend on the
individual’s age and their response to such factors as the activity of
aldose reductase in the lens epithelial cells [22].
Most studies have examined the effects on refractive error of
changing blood glucose levels after insulin treatment has been
instigated for the first time in newly-diagnosed diabetic patients
[2,4,5,7]. Several studies involve small selected subsets of patients
who have recently complained of visual blur, rather than typical,
unselected, diabetic individuals [23,24]. However, such work may
not reflect the response of the eye to the more typical glucose
fluctuations that are experienced by long-term diabetic patients on
a day-to-day basis. To the best of our knowledge, such data are not
readily available. Rubin et al. [25] investigated the diurnal
variation in refractive errors in one diabetic patient versus one
non-diabetic subject using an autorefractor, but found no clinically
significant differences between the subjects. Agardh et al. [26]
found a stable refraction and visual acuity in fifty-three diabetic
patients at different occasions within a month. Since blood glucose
levels in diabetic patients are known to fluctuate significantly
during the day, the aim of the present study was to compare in
detail the short-term daily variation in the refraction, ocular
aberration and ocular components in diabetic patients with those
of control subjects. We found no significant direct correlation
between fluctuating blood glucose levels and refractive error or
ocular biometry in the diabetic eyes.
Methods
This prospective, controlled study was conducted at a single
clinical site (Optegra Birmingham Eye Hospital, formerly known
as The Aston Academy, Life Sciences, Aston University,
Birmingham, United Kingdom). Diabetic patients and control
subjects were recruited from an advertisement placed in a local
newspaper and from a University public access clinic and student
and staff populations.
Ethics Statement
Ethical approval was obtained from the Institutional Research
Ethics Committee and informed consent was obtained from all
subjects, conforming to the tenets of the Declaration of Helsinki.
All subjects attended the clinic between 0800 and 2000 hours,
data being collected at approximately two-hourly intervals (0800,
1030, 1230, 1500, 1700, and 1900 hours). Subjects were screened
to exclude those who had previous ocular surgery, amblyopia,
Snellen acuity worse than 6/9, or past invasive treatment for
diabetic maculopathy, this being checked using non-mydriatic
fundus photography (Canon CR-DGi fundus camera; Canon
USA, Inc. New York, USA) and optical coherence tomography
(Stratus OCT; Carl Zeiss Meditec AG, Jena, Germany). Cataract
was defined as either ‘present’ or ‘not present’ following slit lamp
examination. Cataract was graded using the Lens Opacities
Classification III System [27]. We classified subjects as having no
clinically significant cataract (NO1 or NC1, C1, PS1) or clinically
significant cataract (all others) for the purpose of analysis. The
classification of diabetic retinopathy [28] was determined using
non-mydriatic fundus photography and direct ophthalmoscopy
was performed to confirm the results.
Previously-experienced blurred vision during hypo- or hyper-
glycemia was recorded but not considered as an inclusion
criterion. Contact lens wearers were asked to use their spectacles
on the day of the study and to suspend contact lens wear on the
previous day, to minimise the influence of any short-term corneal
changes induced by contact lens wear. The right or the left eye of
each subject was randomly selected for the clinical assessments.
Subjects were encouraged to eat, drink and use their medications
as they normally would. Breakfast was taken between the first and
the second measurement session, lunch between the third and
fourth session, and dinner between the fifth and sixth set of
measurements.
Measurements of objective refraction and ocular aberrations for
a 6 mm pupil were carried out using an OPD ARK-10000
autorefractometer (Nidek Co., Ltd., Tokyo, Japan). Axial length
and anterior chamber depth were measured using an IOLMaster
(Carl Zeiss Meditec AG, Jena, Germany). Lens thickness
measurements were performed using an Echorule Ultrasonic
Biometer (Vision Care/Phakosystems Inc., Downsview, Canada)
with one drop of topical anaesthetic (oxybuprocaine hydrochloride
0.4% w/v; Chauvin Pharmaceuticals Ltd, Kingston-upon-
Thames, UK), and corneal thickness measurements were obtained
using a Pachmate DGH-550 Pachette 2 (DGH Technology Inc,
Exton, USA) pachymeter, using the same type of anaesthetic. All
the above measurements were repeated 3 times at each time point
(except for pachymetry, where 5 measurements were taken) and
the mean was used for data analysis.
Intersession coefficients of repeatability (COR), given as
61.966 standard deviation of the differences between two sets
of measures taken on the same subjects, have been reported for the
techniques used in the present study. They are: 18.0 mm for
central corneal thickness measured using ultrasound pachymetry
[29]; 0.049 mm and 0.043 mm respectively for anterior chamber
depth and axial length measured using the IOLMaster [30]; and
0.196 mm for lens thickness obtained using ultrasound biometry
[31]. The Nidek OPD autorefractometer has a COR of 0.7–0.8 D
for the vertical and horizontal meridians [32]. Fluctuations in any
of our ocular parameters are only considered to be clinically
significant if they are found to be larger than the COR values.
Information relating to long-term diabetic metabolic control
was obtained from an HbA1c test (blood taken from the forearm
by a nurse and analysed using a laboratory-based Roche Serum
Work Area glucose analyser), and short-term blood glucose
concentration taken from a finger was assessed at each measure-
ment session using a HemoCue 201+ capillary blood test
(HemoCue AB A¨ngelholm, Sweden).
Fundus photography and the HbA1c blood test were performed
in the diabetic patients at baseline only. Autorefraction, aberro-
metry, axial length and anterior chamber depth, corneal thickness,
lens thickness and blood glucose measurement were repeated
approximately every two hours in all diabetic patients and control
subjects.
Statistical Analysis
Manifest auto-refraction in conventional script notation (sphere
S, cylinder C, and axis h, nominally measured to 0.01D and 1
degree) was converted to power vector coordinates as described by
Thibos et al. [33]:
1. Mean spherical equivalent (MSE), using
MSE~Sz
C
2
2. Orthogonal component 90 to 180 degrees of astigmatism (J0),
given by
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J0~{
C
2
cos 2hð Þ
3. Orthogonal component 45 to 135 degrees of astigmatism (J45),
using
J45~{
C
2
sin 2hð Þ
All statistical analyses were performed using SPSS version 19.0
for Windows (SPSS Inc., Chicago, USA). Kolmogorov-Smirnov
tests revealed no significant deviation from a normal distribution
for most of the test parameters (BGLs, CCT, ACD, LT, AL, MSE,
J180, J45 and vertical coma) at baseline (p.0.05). Due to their
statistically significant Kolmogorov-Smirnov results, some ocular
aberrations (horizontal coma, spherical aberrations, and higher-
order RMS) were analysed using non-parametric tests (i.e. Mann-
Whitney U test, Kruskal-Wallis test, and Spearman Rank Order
Correlation for baseline measurements, and Friedman test to
investigate 12-hour fluctuations).
Each variable was first assessed for between-group differences at
baseline. Repeated-measures ANOVA were used to investigate the
variation in parameters over the course of the day. Post hoc
analysis identified any session that showed significant differences
compared to other sessions, or any significant inter-group
differences. For analysis of horizontal coma, spherical aberrations,
and higher-order RMS data, a non-parametric Friedman test was
performed. Additionally, stepwise multiple regression models were
used to explore possible relationships between each test parameter
and a number of potential predictor variables for each of the six
sessions during the day. Two models were designed to explore
differences between the two diabetic groups and the diabetic
versus the control groups separately. The predictor variables of
model 1 were age, duration of the disease, diabetic retinopathy
status (using a classification based on the Early Treatment Diabetic
Retinopathy Study [34]), and blood glucose levels; model 2
included age, disease status (T1DM or T2DM), HbA1c and blood
glucose levels. A p-value of #0.05 was taken to indicate statistical
significance for baseline measurements, while a p-value of #0.01
represented statistical significance in all repeated measures and
multiple regression tests.
Results
Baseline Data
Data on non-optical parameters are given in Table 1. The
T1DM patients were significantly younger than T2DM patients
and the control group (p = 0.004). The control group had
significantly lower blood glucose levels (p,0.0005). No statistically
significant differences were found between the groups for gender,
ethnicity, or the presence of cataract [27] (p.0.05).
Between the diabetic groups, the duration of the disease was
greater in the T1DM patients (p = 0.007). On the basis that an
HbA1c reading of #7.5% indicated reasonably ‘good’ diabetic
metabolic control [35], whereas HbA1c .7.5% was indicative of
‘poor’ metabolic control, the proportion of T1DM with higher
HbA1c readings was greater than in the T2DM group, although
the difference failed to reach statistical significance (p= 0.07).
All the baseline data for patients in the two diabetic groups were
analysed in terms of whether their metabolic control was ‘‘good’’
or ‘‘poor’’ as defined above. Table 2 shows that the diabetic
patients in the well-controlled group had a mean HbA1c of
6.560.7%, while the mean HbA1c value in the poorly-controlled
group was 9.261.7% (p,0.0005). Considering the optical and
biometric data (Table 2), patients with poorly-controlled diabetes
showed a significantly greater central corneal thickness CCT
(t(39) =22.03; p = 0.049), smaller anterior chamber depth ACD
(t(39) = 2.73; p = 0.006), and smaller axial length AL (t(39) = 2.28;
p = 0.03) compared to those with well-controlled diabetes. The
shallower anterior chambers of the poorly-controlled diabetic
patients were accompanied by thicker lenses (even though the
patients were, on average, younger), but the difference in LT
compared with the well-controlled patients was not statistically
significant. Except for J45, which showed a higher mean value in
poorly-controlled compared to well-controlled diabetic patients
(p = 0.03), no differences between these two groups were found for
refractive components, individual aberrations, or total RMS
wavefront error.
When data for all the diabetic and control subjects were pooled,
age was found to have a significant effect on ACD and LT. ACD
was found to become shallower with age (F(2,58) = 5.22;
p = 0.008), and LT was found to increase with age
(F(2,58) = 5.03; p= 0.01). The MSE values in diabetic and control
subjects ranged from –9.63D to 8.75D. Post-hoc analysis among
the different age groups revealed higher levels of myopia in
younger subjects (,30 years) compared to older subjects (.60
years) (F(2,58) = 5.42; p= 0.006). Subjects in the age-range 31–59
years did not show a significant difference in MSE compared to
the ,30 or .60 year old subject groups (p.0.05). There were no
differences in the amount of oblique astigmatism for sub-groups
split by gender, age or by the degree of diabetic retinopathy
present. However, posthoc analysis revealed an increased J45
value in T1DM compared to T2DM patients (p = 0.005). A
significant positive correlation was found between the J45 value
and the duration of disease (r = 0.425; p = 0.006).
12-hour Fluctuations
As expected, blood glucose levels were found to vary
significantly within groups (p,0.0005) and between groups
(p,0.0005). The short-term changes in blood glucose concentra-
tion for the three groups are shown in Figure 1. Since the variance
in blood glucose levels at each session was large in the diabetic
groups, the error bars show 61 standard error of the mean
(SEM=SD/!n). The largest changes, of up to about 6 mM/l,
occur in T1DM, the smallest in the controls. As the mean baseline
blood glucose levels are also highest for the T1DM group and
smallest for the controls (Table 2), the differences between the
groups are reduced if the changes are normalised in terms of the
baseline values (i.e. normalised change= absolute change/baseline
level).
Data for the 12-hour variation in the components of refractive
error (MSE, J0, and J45) are shown in Figure 2, plotted in terms of
the change from the baseline value of the parameter. All dioptric
changes are small and close to the limits set by the reliability of the
measurement equipment used (but note that since J0 and J45 are
cross-cylinders, the changes in cylindrical correction C are twice
those in J0 and J45). Changes in several of the key biometric
parameters are presented in Figure 3A as departures from their
baseline values. Figure 3B gives the data in a different form, the
absolute values of each parameter at each point in time being
normalised in terms of the baseline value of the parameter. Again,
the magnitudes of any of the changes observed are close to the
Stability of Refraction in Diabetes
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Table 1. Patient demographics.
T2DM patients T1DM patients Control subjects p-value
Subjects 21 20 20
(Number)
Age 56611 38614 49623 0.004*
(Mean 6 SD in years)
Gender 12:9 9:11 11:9 0.7
(male: female)
Ethnicity 18:2:1 17:1:2 18:2:0 0.9
(Caucasian: Asian: Black)
Eye 12:9 10:10 11:9 0.9
(right: left)
Cataract 6:15 3:17 6:14 0.5
(present: not present) [27]
Diabetic retinopathy 9:10:2 10:5:5 – 0.7
(none: background: pre-proliferative) [28]
Duration of the disease 1268 23615 – 0.007*
(Mean 6 SD in years)
HbA1c level 7.561.8 8.661.9 5.560.5 0.07 (DM only)
(%) ,0.0005* (DM+control)
Diabetic control 14:7 4:16 – 0.07
(HbA1c #7.5 mM/l (135 mg/dl): HbA1c .7.5 mM/l)
Glucose levels 8.363.0 11.165.0 4.660.5 ,0.0005*
mM/l (mg/dl) (149654) (200690) (8369)
HemoCue range: 0–22.2 mM/l
Diabetic medication 7:6:7:1 20:0:0:0 –
(insulin: tablets: both: diet only)
Where data for three groups are given, P values refer to probabilities that the parameter differs significantly between the 3 groups, otherwise the probabilities refer to
differences between the two diabetic groups.
*indicates a statistically significant p-value of #0.05.
doi:10.1371/journal.pone.0052947.t001
Table 2. Baseline data for well-controlled (HbA1c #7.5%) and poorly-controlled (HbA1c .7.5%) diabetic patients (including both
T1DM and T2DM) for all ocular parameters.
Well-controlled Poorly-controlled p-value
Subjects (number) 18 23
HbA1c (mean 6 SD in %) 6.560.7 9.261.7 ,0.0005*
Age (mean 6 SD in years) 54614 42615 0.01*
MSE (mean 6 SD in Diopters) 20.6362.28 0.03362.44 0.38
J0 (mean 6 SD in Diopters) 20.0260.28 20.0260.31 0.99
J45 (mean 6 SD in Diopters) 20.1560.26 0.0460.28 0.03*
CCT (mean 6 SD in microns) 535636 560642 0.049*
ACD (mean 6 SD in mm) 3.2860.24 3.0560.32 0.01*
LT (mean 6 SD in mm) 4.1260.70 4.4560.56 0.13
AL (mean 6 SD in mm) 23.8361.07 23.0361.15 0.03*
Horizontal coma (mean 6 SD in microns) 20.3460.19 20.1260.18 0.38
Vertical coma (mean 6 SD in microns) 0.0560.13 20.0460.43 0.58
Spherical aberrations (mean 6 SD in microns) 0.2160.41 0.0360.15 0.21
RMS error (mean 6 SD in microns) 0.5860.25 0.6960.99 0.78
Aberrations were measured for 6 mm pupils.
*indicates a statistically significant p-value of #0.05.
doi:10.1371/journal.pone.0052947.t002
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limits set by the coefficients of repeatability of the instruments used
(see Methods section). With this proviso, several variables showed
small but statistically significant differences either with time (for all
subjects) or between the three groups (T1DM, T2DM, or control).
Post-hoc analysis showed that the CCT was higher at baseline
compared to at all other times during the day (t-test; p,0.0005),
the ACD was significantly shallower at baseline (0800 hours)
compared to at 1230, 1700, and 1900 hours (t-test; p,0.003).
T2DM patients showed a longer AL in the evening (1900 hours)
compared to that measured at baseline (p = 0.002) and T1DM had
a shorter AL in the evening (1900 hours) compared to that
measured around midday (1230 hours) and the afternoon (1700
hours) (p,0.0005 and p= 0.001 respectively). No significant
change in AL was found throughout the day in the non-diabetic
control subjects. Considering inter-group differences, LT showed a
significant difference in fluctuation over the 12-hour period
between groups (p = 0.007). A consistently thicker lens compared
to baseline was found in T2DM versus control subjects (Tukey’s
HSD; p= 0.006). There was no statistically significant difference
between the LT variation in T1DM compared to T2DM
(p= 0.42), or T1DM versus control subjects (p = 0.11).
Multiple Regression Analysis
Multiple regression models were used to investigate the possible
influence of the predictor variables age, disease status, duration of
the disease, blood glucose levels, HbA1c levels, and diabetic
retinopathy on the biometric study parameters. Both models were
applied to each measurement session separately and analysis was
performed to ensure there was no violation of the assumptions of
normality and linearity. If the predictor variable showed a
statistically significant result at 3 or more out of the 6 sessions, it
was considered that the predictor variable had a significant
influence on the biometric parameter of interest. These analyses
revealed that an increase of 4.5 mM/l (81 mg/dl) in blood glucose
levels corresponded with an increase of 10 mm in CCT in the
diabetic patients and control subjects. On average, ACD reduced
by approximately 0.07 mm for every 10 years of age. However,
when diabetic patients were studied separately, ACD decreased by
0.13 mm for every 10 years the patient had diabetes. Additionally,
an increase of 2% in HbA1c corresponded to a decrease in the
ACD of 0.12 mm. The model predicted that LT increases by
approximately 0.13 mm for every 10 years of age for all subjects.
In diabetic patients, the LT increased by around 0.24 mm for
every 10 years of duration of disease, and an increase of 2% in
HbA1c levels corresponded to an increase in LT of 0.21 mm. The
mean spherical equivalent showed an increase of 0.52D every 10
years of age for all subjects, while no difference was found between
the diabetic and non-diabetic subjects. No relationships with any
of the predictor variables were found for AL, J0, J45, and ocular
aberrations.
Discussion
Changes in refractive error in uncontrolled or undiagnosed
diabetic patients have often been reported, although there is
uncertainty about the precise mechanism of such changes. Much
of the literature involves patients who have only just commenced
treatment [2,4,5,7,8,36] or who have recently reported that their
vision had become blurred [23,37].
The present study investigated changes in the refractive optics of
the eyes in long-term diabetic patients and control subjects over a
period of 12 hours, in relation to normal acute, non-fasting, short-
term changes in blood glucose levels. It was hypothesised that with
increasing blood glucose levels the refractive error of diabetic eyes
Figure 1. Change in blood glucose levels from baseline over time for each group. T2DM are represented as diamonds; T1DM are
represented as squares; control subjects are represented as triangles. The error bars represent 1 standard error of the mean (SD/!n). Subjects ate their
meals around 0900, 1330 and 1730 hours. Mean baseline blood glucose levels as determined with the Hemocue test were 11.165.0 mM/l
(200690 mg/dl) for the T1DM; 8.363.0 mM/l (149654 mg/dl) for T2DM; and 4.660.5 mM/l (8369 mg/dl) for the control subjects.
doi:10.1371/journal.pone.0052947.g001
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would alter, possibly towards myopia, while the non-diabetic
subjects’ refractive error was expected to stay more or less constant
over the course of the day. Additionally, we hypothesised that
diabetic patients would show greater short-term variation in the
anterior ocular parameters than control subjects, and possibly
larger changes in refractive indices of these ocular components,
these leading to any refractive changes observed. Although we
found marginally significant baseline differences in anterior
chamber depth in poorly-controlled compared to well-controlled
diabetic patients, the mean changes in the refractive parameters
throughout the day in the diabetic patients were clinically
insignificant (,0.25 D in MSE) and similar to those in the non-
Figure 2. Mean changes over time in the components of refractive error (MSE, J0, and J45) from baseline measurements for each
group. T2DM are represented as diamonds; T1DM are represented as squares; control subjects are represented as triangles. The error bars show 6
SEM.
doi:10.1371/journal.pone.0052947.g002
Figure 3. Mean change from baseline measurements for ocular parameters CCT, ACD, LT, and AL over time for each group (A) and
the relative value of each parameter (i.e. the absolute value of the parameter divided by its baseline value) as a function of time (B).
T2DM are represented as diamonds; T1DM are represented as squares; control subjects are represented as triangles. The error bars show 6 SEM.
doi:10.1371/journal.pone.0052947.g003
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diabetic subjects. Similarly, there was no evidence that ocular
aberrations were systematically higher at baseline in diabetic
patients as compared to controls, or that any aberration
(horizontal or vertical coma, spherical aberrations, or RMS error)
showed greater temporal variation in the diabetic groups.
The absence of significant short-term refractive changes
appears, at first sight, to be incompatible with the results of one
of the few studies to have investigated acute ocular changes with
fluctuating blood glucose levels. Although Wiemer et al. found no
significant changes in the shape of the cornea or lens in 25 diabetic
patients after hyperglycemia [37]; nine of their patients showed
small but significant hyperopic or myopic shifts. However, in
contrast to our study, Weimer et al.’s patients returned for the
second visit on another day (average 51 days later) and their
results could therefore refer to longer-term rather than true acute
ocular changes. Moreover, their patients were selected on the basis
that they initially complained of blurred vision. A different study
conducted by the same authors [24] revealed no changes in
refractive properties after acute (30 minute intervals) changes in
blood glucose levels. However, the subjects in this study had been
rendered ‘diabetic’ by somatostatin injection which raised the
blood glucose level by around 15 mM/L. This approach has been
used previously for similar research purposes [1,38] but it is not
clear whether it adequately simulates the behaviour of real diabetic
patients [1,39]. Similarly, as noted earlier, most of the studies
reporting marked refractive change involve patients who have
either just commenced treatment or who have recently reported
that their vision had become blurred. Thus the composition of our
patient groups is substantially different (and possibly more
representative of the general population of diabetics) which may
partly explain the different results found.
It is also helpful to consider here the timescales of possible
changes in blood sugar level and refraction as revealed by previous
studies. Okomoto et al. [4] found that patients whose marked
initial hyperglycaemia (blood glucose level $22 mM/l) was being
brought under control (to around 6 mM/l) typically experienced a
hyperopic refractive shift which peaked between 3 and 30 days
after commencement of treatment. The delay and the magnitude
of the refractive shift increased with the initial blood glucose level.
Refractive recovery times extended from about 12 to 90 days, with
the longest times being associated with the largest initial refractive
changes. Patients with an initial blood glucose level of 22 mM/l
typically showed hyperopic shifts of only about 0.6 D, the peak of
this change being reached about 7 days after commencement of
treatment and decaying to zero after about 28 days. Broadly
similar results were found by Giusti [2]. The modest, and relatively
slow, refractive changes in response to changes in blood glucose
levels of about 16 mM/l suggest that it is not surprising that our
much smaller and more transient changes in blood glucose (a
maximum of around 6 mM/l for the T1DM group on a timescale
of a few hours, see Figure 1) failed to cause any detectable
refractive change. It would appear to be reasonable to suppose
that the time constants of any processes affecting the gradients of
refractive index within the lens are too long for small, short-term
changes in blood glucose to have any significant effect on
refraction.
A clear limitation of the present study is the relatively small
number (41) of diabetic patients involved. While our finding of
minimal refractive or aberrational change in the presence of
normal, modest, diurnal fluctuations in blood sugar level may be
typical of such patients, we cannot rule out the possibility that, in a
larger population, some individuals may display marked acute
changes in either or both blood sugar and refraction. None of our
patients complained of blurred vision during the measurement
period and it may be that, had our patients been selected on the
basis of such complaints, refractive changes might have been
observed [37]. A further limitation is the substantial range in age
and duration of disease in our diabetic groups, which might be
expected to increase the variation across subjects and make subtle
changes more difficult to detect: we found it difficult to recruit
more homogeneous groups willing to undertake the lengthy set of
measurements involved in the study.
While no significant diurnal changes were found in the vector
components of refraction, the variations in other optical and
biometric parameters are of interest. Short-term variations in
CCT have been described previously in non-diabetic eyes [40,41].
Like the present study and despite differences in instrumentation
used and time course studied, these previous studies show that the
cornea is thickest immediately after awakening [40,42]. In our
study the short-term variation in CCT (around 5 mm) was similar
in the control subjects and the diabetic patients and, even though
the diabetic corneas were thicker compared to the controls, there
were no significant differences between the three groups at
baseline. This suggests that short-term changes in blood glucose
levels do not have a significant effect on the CCT in diabetic
patients. However, any difference in short-term CCT variation
between the diabetic and non-diabetic corneas could have been
masked by the decreased corneal deswelling response known to
occur in diabetic patients [43,44]. This could also explain the
significantly thicker corneas in poorly-controlled compared to
well-controlled diabetic patients. Additionally, our results showed
that the ACD was significantly decreased in poorly-controlled
diabetic subjects compared to the well-controlled group. This does
not appear to have been reported previously. It is of interest that
ACD increased after baseline in all subjects, by around 50 mm. It
may be that this is due to a posterior movement of the anterior
surface of the lens following a slight relaxation of accommodation:
the measurements of LT are not sufficiently sensitive to confirm
this. No previous study has reported short-term variation in LT
and our data also failed to show significant differences in
fluctuation in the LT during the day in the diabetes versus the
control subjects (p = 0.86). Since it is difficult to completely control
accommodation using A-scan biometry, it was concluded that
small changes in lens thickness or curvatures, which might occur in
diabetic patients, could only be measured clinically if (micro-)
fluctuations in accommodation were eliminated.
Over the 12-hour period, a significant increase in AL occurred
in T2DM patients with the greatest value being measured at 1900
hours. The control subjects did not show a significant short-term
variation in AL, although these subjects did show an increased AL
in the middle of the day, in agreement with Stone et al. [45] Our
results also show that the mean absolute maximum change in AL
during the day was 13 mm in T2DM (p= 0.002); 14 mm in T1DM
(p= 0.01); and 14 mm in the control subjects (p = 0.01). All these
figures are at the limits of the resolution of the IOLMaster.
However, if the optical power of the eye remains constant, a 1 mm
shift in the AL from the cornea to Bruch’s membrane corresponds
to about 2.7D of optical defocus [46]. As a result, the mean short-
term AL fluctuation, 14 mm, would correspond to a short-term
shift of only 60.038D. Assuming that the depth-of-focus of the
human eye is approximately 0.3D [46], this short-term variation in
AL is too small to be appreciated subjectively or measured
clinically. The observed increase in AL at the last session in T2DM
compared to baseline could not have been induced by corneal
thickness changes, as the profiles do not overlap. Possible reasons
for the difference, if any, in the short-term cycle of AL
measurements between T1DM and T2DM patients could be
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nutritional (carbohydrate intake), as previously suggested by Stone
et al. [45].
As already remarked, none of our diabetic patients complained
of marked changes in the clarity of their vision during the limited
12-hour test period. Nevertheless the possibility that vision may
become degraded in the absence of optical change [37], perhaps
due to neural factors, is an interesting one. Further studies in
which temporal changes in visual performance, in terms of, e.g.,
visual acuity or contrast sensitivity, are measured at the same time
as blood sugar levels and the optical characteristics of the eye
should help to clarify this question.
Conclusions
Contrary to our expectations, this study showed that, in the
relatively small (41) number of long-term diabetics studied, typical
short-term (12 hours) fluctuations in blood glucose levels did not
induce clinically-detectable short-term changes in refractive error,
ocular aberrations or the anterior ocular biometric parameters.
Nevertheless, some diabetic patients do complain about their
vision during hypoglycaemia and hyperglycaemia and previous
studies of the subset of patients with such complaints have
demonstrated that, in some cases, changes in blood sugar levels are
accompanied by refractive change. We note, however, that in such
patients the blood sugar changes may be much larger than in our
work and that the refractive changes may occur over much longer
timescales than a single day. It may also be that fluctuations in
vision in at least some diabetic patients are caused by factors other
than refractive error fluctuations.
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